Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma
Salvia Jain(Broad Institute), David Avigan(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Parul Bhargava(Beth Israel Deaconess Hospital), Maxwell Coll, Hasan Rajabi(Harvard University), Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), Katarina Luptakova(Tesaro (United States)), Donald Küfe(Dana-Farber Cancer Institute), Athalia R. Pyzer, Thomas S. Kupper(Brigham and Women's Hospital), Michal Bar‐Natan(NewYork–Presbyterian Hospital), Yin Li(Third Affiliated Hospital of Sun Yat-sen University), Dina Stroopinsky(Beth Israel Deaconess Medical Center), Maroof Alam(Dana-Farber Cancer Institute), Jon Arnason(Beth Israel Deaconess Medical Center), Kristen Palmer(Beth Israel Deaconess Medical Center), Rachael A. Clark(Brigham and Women's Hospital)
Cited by 37
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
|New England Journal of Medicine|2011|1.1k